- Home
- RLAY vs ATYR Comparison
RLAY vs ATYR Comparison
Compare RLAY & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- ATYR
- Stock Information
- Founded
- RLAY 2015
- ATYR 2005
- Country
- RLAY United States
- ATYR United States
- Employees
- RLAY N/A
- ATYR N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RLAY Health Care
- ATYR Health Care
- Exchange
- RLAY Nasdaq
- ATYR Nasdaq
- Market Cap
- RLAY 619.0M
- ATYR 535.0M
- IPO Year
- RLAY 2020
- ATYR 2015
- Fundamental
- Price
- RLAY $3.99
- ATYR $6.03
- Analyst Decision
- RLAY Strong Buy
- ATYR Strong Buy
- Analyst Count
- RLAY 13
- ATYR 5
- Target Price
- RLAY $18.00
- ATYR $23.25
- AVG Volume (30 Days)
- RLAY 1.2M
- ATYR 4.9M
- Earning Date
- RLAY 11-05-2025
- ATYR 11-06-2025
- Dividend Yield
- RLAY N/A
- ATYR N/A
- EPS Growth
- RLAY N/A
- ATYR N/A
- EPS
- RLAY N/A
- ATYR N/A
- Revenue
- RLAY $8,355,000.00
- ATYR N/A
- Revenue This Year
- RLAY $31.55
- ATYR $478.72
- Revenue Next Year
- RLAY N/A
- ATYR $1,899.26
- P/E Ratio
- RLAY N/A
- ATYR N/A
- Revenue Growth
- RLAY N/A
- ATYR N/A
- 52 Week Low
- RLAY $1.78
- ATYR $1.67
- 52 Week High
- RLAY $8.32
- ATYR $7.29
- Technical
- Relative Strength Index (RSI)
- RLAY 58.70
- ATYR 62.69
- Support Level
- RLAY $3.87
- ATYR $5.08
- Resistance Level
- RLAY $4.20
- ATYR $5.77
- Average True Range (ATR)
- RLAY 0.21
- ATYR 0.47
- MACD
- RLAY 0.03
- ATYR 0.04
- Stochastic Oscillator
- RLAY 66.87
- ATYR 68.03
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.